3/5/2009

Regulus Therapeutics has secured $20 million in a first round of funding from Alnylam Pharmaceuticals and Isis Pharmaceuticals. Alnylam and Isis formed Regulus in 2007 to focus on the development and marketing of microRNA-based drugs.

Related Summaries